Ipilimumab

Drugs in R and D

Volumn 10, Issue 2, 2010, Pages 97-110

[No Author Info available]

Author keywords

general; Ipilimumab; Lymphoma; Malignant melanoma; Non small cell lung cancer; Prostate cancer; Research and development; treatment

Indexed keywords

BUDESONIDE; CARBOPLATIN; DACARBAZINE; DOCETAXEL; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; IPILIMUMAB; MDX 101; MDX 1379; PACLITAXEL; PEPTIDE VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADRENAL INSUFFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLITIS; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; DERMATITIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPOPITUITARISM; IMMUNOGENICITY; INTESTINE PERFORATION; KIDNEY CANCER; LARYNX SPASM; LIVER DISEASE; LUNG ALVEOLITIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTASIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; T LYMPHOCYTE ACTIVATION; THYROID FUNCTION TEST; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR; UROTHELIAL CANCER; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MELANOMA; PROSTATIC NEOPLASMS;

EID: 79953193062     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11584510-000000000-00000     Document Type: Article

References (51)

1. Decision Resources. A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Higher Patient Share in the U. S. Than in Europe. www.decisionre sources.com, 19 Jan 2009 Media Release
2. Bristol-Myers Squibb Company. Bristol-Myers Squibb Completes Acquisition of Medarex, Inc. www.bms.com, 02 Sep. 2009 Media Release
3. Bristol-Myers Squibb Company, Medarex Inc. Bristol-Myers Squibb and Medarex Global Development and Commercialization Collaboration for MDX-010 Becomes Effective. http://www.medarex.com, 13 Jan 2005 Media Release
4. Cell Genesys. Cell Genesys Announces Tender Offer Results While Continuing to Pursue Strategic Alternatives. www.cellgenesys.com, 23 Jun. 2009 Media Release
5. The Angeles Clinic and Research Institute. The Angeles Clinic and Research Institute Announces Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma. www.theangelesclinic.org, 06 Jun. 2010 Media Release
6. Bristol-Myers Squibb Company. Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma. www.bms.com, 06 Jun. 2010 Media Release
7. Medarex Inc. Medarex Receives FDA Fast Track Designation for MDX-010 Treatment of Metastatic Melanoma. www.medarex.com, 05 Oct. 2004 Media Release
8. Medarex Inc. Medarex Commences Enrollment in Phase III Clinical Trial for MDX-010 in Metastatic Melanoma. http://www.medarex.com, 28 Sep. 2004 Media Release
9. Medarex Inc. Medarex Announces Special Protocol Assessment Agreement with FDA to Initiate Phase III Clinical Trial for MDX-010 in Metastatic Melanoma. www.medarex.com, 23 Aug. 2004 Media Release
10. Bristol-Myers Squibb, Medarex Inc. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma. www.medarex.com, 10 Dec. 2007 Media Release
11. Bristol-Myers Squibb Company, Medarex Inc. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab. www.medarex.com, 25 Apr. 2008 Media Release
12. Medarex Inc. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City. www.medarex.com, 26 Mar. 2009 Media Release
13. Medarex Inc. Medarex Announces Ipilimumab Program Continues to Move Forward. www.medarex.com, 03 Apr. 2008 Media Release
14. Medarex Inc. Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line use in Combination with Chemotherapy and Second-Line use as Monotherapy. www.medarex.com, 07 Dec. 2006 Media Release
15. Medarex Inc. Medarex Announces Special Protocol Assessment Agreement With the FDA to Initiate Registrational Trial for Ipilimumab (MDX-010) Combination With Chemotherapy in First-Line Metastatic Melanoma Patients. www.medarex.com, 19 Jun. 2006 Media Release
16. Bristol-Myers Squibb Company. Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer. www.bms.com, 22 May 2010 Media Release
17. Medarex Inc. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting. www.medarex.com, 15 Apr. 2008 Media Release
18. Medarex Inc. Medarex and Cell Genesys Initiate Phase I Clinical Trial of MDX-010 in Combination with GVAX (R) Prostate Cancer Vaccine. http://www.medarex.com, 13 Sep. 2004 Media Release
19. Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody. www.cell genesys.com, 04 Jun. 2007 Media Release
20. Medarex Inc. Ipilimumab (MDX-010) Safety and Clinical Response Data in Lymphomas and Leukemia Presented at the 48th American Society of Hematology Annual Meeting. www.medarex.com, 11 Dec. 2006 Media Release
21. Hodi FS, Seiden M, Butler M, et al. Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). 40th Annual Meeting of the American Society of Clinical Oncology: 172, Jun. 2004. USA. [English]
22. Bristol-Myers Squibb Company, Medarex Inc. Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year. www.bms.com, 16 Sep. 2008 Media Release
23. Weber JS, Berman D, Siegel J, et al. Clinical activity of ipilimumab in patients with advanced melanoma and brain metastases. 33rd Congress of the European Society for Medical Oncology: abstr. 786P, 12 Sep. 2008. Available from URL: http://annonc.oxfordjournals.org. USA. [English]
24. Ron I, Berman D, Siegel J, et al. Efficacy and safety of patients with advanced melanoma treated with ipilimumab with or without the addition of prophylactic budesonide. 33rd Congress of the European Society for Medical Oncology: abstr. 783P, 12 Sep. 2008. Available from URL: http://annonc. oxfordjournals.org. Israel. [English]. Clinical Trials Insight
25. Lebbe C, Hoos A, Chin K, et al. Effect of dose on efficacy and safety in ipilimumab-treated patients with advanced melanoma - results from a phase II, randomized, doseranging study. 33rd Congress of the European Society for Medical Oncology: abstr. 769O, 12 Sep. 2008. Available from URL: http://annonc. oxfordjournals.org. France. [English]. Clinical Trials Insight
26. Weber JS, The Global Ipilimumab Melanoma Study Group. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: (plus oral presentation) abstr. 9010, 30 May 2008. Available from URL: http://www.asco.org. Unknown. [English]. Clinical Trials Insight
27. Bristol-Myers Squibb Company, Medarex Inc. Phase II Clinical Study of MDX-010/MDX-1379 Combination Shows Durable Responses in Patients with Metastatic Melanoma. www.medarex.com, 20 Apr. 2005 Media Release
28. Medarex Inc. Interim Ipilimumab (MDX-010) Phase II Trial Results Indicate Well-Tolerated, Extended Dosing with Preliminary Evidence that Immune Activation May Reduce Relapse in the Adjuvant Setting in Melanoma. www.medarex.com, 05 Jun. 2006 Media Release
29. Bristol-Myers Squibb, Medarex Inc. Medarex and Bristol-Myers Squibb Announce Complete and Partial Responses Observed in Phase I/II Clinical Study of MDX-010 in Combination with Il-2. www.medarex.com, 07 Mar. 2005 Media Release
30. Jaber S, Cowen E, Haworth L, et al. A CD4 T cell predominant dermatitis in stage IV melanoma patients treated with anti-CTLA-4 monoclonal antibody as a single agent. Journal of Investigative Dermatology. 124 (Suppl.): 37, No. 4, Apr. 2005. USA. [English]
31. Medarex Inc. Ipilimumab (MDX-010) Shows Encouraging Data in Phase I and Phase II Clinical Trials for Hormone Refractory Prostate Cancer Patients. www.medarex.com, 05 Jun. 2006 Media Release
32. Kavanagh B, Rini B, Weinberg V, et al. CTLA-4 blockadebased immunotherapy for hormone-refractory prostate cancer. 2006 Prostate Cancer Symposium: abstr. 255, 24 Feb. 2006. Unknown. [English]
33. Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex Announce Encouraging Interim Results from a Phase 1 Combination Therapy Trial With GVAX (R) Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody. www.cellgenesys.com, 03 Jun. 2006 Media Release
34. Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration resistant prostate cancer. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 5004, 30 May 2008. Available from URL: http://www.asco.org. Unknown. [English]
35. Hoos A, Chasalow SD, Parker SM, et al. Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma. 33rd Congress of the European Society for Medical Oncology: abstr. 785P, 12 Sep. 2008. Available from URL: http://annonc.oxfordjournals.org. USA. [English]. Clinical Trials Insight
36. Cell Genesys Inc. Cell Genesys Reports Data on an Association Between Immune Response and Anti-Tumor Activity in Patients Receiving GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010). www.cell genesys.com, 16 Apr. 2008 Media Release
37. Bristol-Myers Squibb Company, Medarex Inc. Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg). www.bms.com, 01 Jun. 2009 Media Release
38. Bristol-Myers Squibb Company, Medarex Inc. New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting. www.medarex.com, 02 Jun. 2008 Media Release
39. Urba WJ, Weber JS, O'Day SJ, et al. Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing). 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 3018, 30 May 2008. Available from URL: http://www.asco.org. [English]
40. Harmankaya K, Pehamberger H, Hoos A, et al. Ipilimumab mediated patterns of response in patients with pretreated, advanced melanoma. 33rd Congress of the European Society for Medical Oncology: abstr. 784P, 12 Sep. 2008. Available from URL: http://annonc.oxfordjournals.org. Austria. [English]
41. Maio M, Hoos A, Ibrahim R, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study. 33rd Congressof the European Society for Medical Oncology: abstr. 776PD, 12 Sep. 2008. Available from URL: http://annonc.oxfordjournals.org. Italy. [English]
42. Powderly JD, O'Day SJ, Hersh EM, et al. Prolonged survival in objective responders to ipilimumab therapy. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 20004, 30 May 2008. Available from URL: http://www.asco.org. [English]
43. Thompson JA, The Global Ipilimumab Melanoma Study Group. Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 9055, 30 May 2008. Available from URL: http://www.asco.org [English]
44. Medarex Inc. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma. www.medarex.com, 01 Jun. 2008 Media Release
45. Medarex Inc. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab. www.bms.com, 05 Jun. 2007 Media Release
46. Medarex Inc. Anti-Cancer Responses in Metastatic Melanoma Patients Linked to Immune Activation by MDX-010 Published in the 'Proceedings of the National Academy of Sciences' (PNAS). www.medarex.com, 25 Jun. 2003 Media Release
47. Medarex. 22nd Annual JP Morgan Healthcare Conference January 14, 2004 Internet Document: [18 pages], 14 Jan 2004. Available from URL: http://www.medarex.com. USA. [English]
48. Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase 1 Combination Therapy Trial With GVAX (TM) Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody. www.cellgenesys.com, 22 Feb. 2007 Media Release
49. Fong L, Kwek S, Kavanagh B, et al. CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent induction of CD8+ T cell activation and clinical responses. 99th Annual Meeting of the American Association for Cancer Research: 601-602, 12 Apr. 2008. USA. [English]
50. Yang JC, Beck KE, Blansfield JA, et al. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). Journal of Clinical Oncology. 23 (Suppl.): 166 (plus oral presentation) abstr. 2501, No. 16, Part I, 1 Jun. 2005. USA. [English]. Clinical Trials Insight
51. Medarex Inc. Medarex reports interim finding of outgoing phase I/II clinical trials of fully human antibody for melanoma and prostate cancer. Media Release: [2 pages], 30 Oct. 2001. Available from URL: http://www.medarex.com. USA. [English]